PubMed HealthSearch

PubMed · 3325218

Pancreatic B-cell function during normal pregnancy.

Abstract

24-h urinary C-peptide excretion was studied in 19 healthy normal weight women with normal glucose tolerance, and related to weight gain and skinfold thickness at 12, 20, 30, 36 weeks of gestation and 6-8 weeks post partum. The urinary C-peptide values (total nmoles or nmoles per kg body weight) showed a significant and progressive increase with gestation. The average C-peptide value was already at 12 weeks of gestation 4 times higher than under non-pregnant conditions. The urinary C-peptide excretion was neither related to maternal weight, weight gain or skinfold thickness at any of the observation periods during pregnancy, nor to the plasma C-peptide response to an oral glucose load at 32 weeks of gestation. A significant correlation was found between urinary C-peptide excretion and body weight determined post partum (r = 0.54, p less than 0.05). The increment in urinary C-peptide excretions at 12 weeks of gestation was unrelated to body mass, suggesting that insulin resistance is present already at this early stage of normal gestation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Nordlander, U Hanson, B Persson, M Stangenberg. 1987. Pancreatic B-cell function during normal pregnancy.. https://pubmed.ncbi.nlm.nih.gov/3325218/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Plasma glicentin in diabetic and gastrectomized patients.

Recent successful synthesis of human glicentin prompted us to establish an immunoassay method for determination of human glicentin in plasma. Human glicentin in plasma was measured using a newly developed sandwich ELISA. The mean fasting levels of human glicentin were 18.6+/-2.4 and 19.7+/-2.1 pM in normal subjects and diabetic patients, respectively. In diabetic patients with renal failure, plasma glicentin was elevated, exceeding 100 pM. In normal subjects, plasma glicentin increased to a peak level of about 130 pM at 60 min after an oral glucose load, and then decreased. In patients who underwent gastrectomy, plasma glicentin rapidly increased to a peak of about 300 pM at 30 min after oral glucose load. In a patient with short bowel syndrome plasma glicentin did not change following an oral glucose load. These results correspond with previous findings for gut glucagon-like immunoreactive materials (GLI) or enteroglucagon. We conclude that glicentin is secreted from the small intestine in response to intraluminal glucose stimulation in humans.

Blood Glucose

[Diagnostic criteria for type 2 diabetes].

A new definition of diabetes is just about to be adopted by WHO. The main change concerns the glycemic threshold for diagnosis of diabetes. Its value will decrease from 7.7 mmol/L to 7 mmol/L. This drop is neither the consequence of a methodological change (diabetes remains defined by glycemic values at risk of retinopathy) nor a revision of the gold standard (glycemic value > or = 11 mmol/L at 2 h. post glucose load remains the most accurate criterion for diagnosis). The only purpose of the new definition is to better correlate fasting glycemia with the 2 h. post load value during OGTT. So, the new definition of diabetes with a glycemic value > or = 7 mmol/L will allow to do diagnosis without OGTT. The WHO experts hope that this simplification will improve the earliness of diagnosis and treatment. WHO will propose to categorize 3 groups according to glycemic values: normal values < 6.05 mmol/L, diabetic values > 7 mmol/L, and impaired fasting glucose encompassing values above normal but below the diagnosis cut-off for diabetes (plasma glucose > or = 6.05 mmol/L to < 7.0 mmol/L). This impaired fasting glucose should be considered as a risk factor for diabetes and cardiovascular disease.

Blood Glucose

[Insulin in the treatment of type 2 diabetes].

Insulin use in NIDDM is a frequent situation. Many acute clinical circumstances justify a transient insulin therapy including ketoacidosis decompensation or hyperosmolar state and severe intercurrent diseases. The problem is more complex when glycemic control is no longer obtained despite maximal doses of oral treatment. Type 2 diabetes is then defined as an insulin-requiring diabetes. There is actually no consensus, but lots of arguments advocate an intensive insulin therapy based on multiple daily injections in this clinical state. However, when patient's overweight is important or if the clinical context is unfavourable, conventional insulin therapy or combined treatment using bedtime insulin and daytime oral agents may be tried.

Blood Glucose